How to Trip Rapid Review
Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)
Step 2: press
Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.
- 5,125 results
- Evidence type
- Clinical Area
Use check boxes to select individual results below
SmartSearch available
Trip's SmartSearch engine has discovered connected searches & results. Click to show301. COVID-19 rapid guideline: gastrointestinal and liver conditions treated with drugs affecting the immune response
reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 4 of 111 1 Communicating with patients and minimising Communicating with patients and minimising risk risk 1.1 Communicate with patients, their families and carers, and support their mental wellbeing to help alleviate any anxiety and fear they may have about COVID-19. Signpost to charities (such as Crohn's & Colitis UK, the British Liver Trust, the Crohn's in Childhood Research Association
2020 National Institute for Health and Clinical Excellence - Clinical Guidelines
302. COVID 19 rapid guideline: renal transplantation
Communication and minimising risk Communication and minimising risk 6.1 Communicate with patients, potential living donors, their families and carers, and support their mental wellbeing to help alleviate any anxiety they may have about COVID-19. Signpost to sources of information, support groups (including NHS Volunteer Responders) and government guidance. For example: • UK government guidance on the mental health and wellbeing aspects of COVID-19 • Kidney Care UK COVID-19 guidance for patients with kidney
2020 National Institute for Health and Clinical Excellence - Clinical Guidelines
303. COVID-19 rapid guideline: acute kidney injury in hospital
#notice-of-rights). Page 5 of 151 1 Communicating with patients Communicating with patients 1.1 Communicate with patients, their families and carers, and support their mental wellbeing to help alleviate any anxiety they may have about COVID-19. Signpost to charities (such as Kidney Care UK, National Kidney Federation and local kidney patient organisations) and support groups (including NHS Volunteer Responders) and UK government guidance on the mental health and wellbeing aspects of COVID-19. COVID-19
2020 National Institute for Health and Clinical Excellence - Clinical Guidelines
304. COVID-19 rapid guideline: children and young people who are immunocompromised
with patients and minimising Communicating with patients and minimising risk risk 1.1 Communicate with patients and their parents or carers, and support their mental wellbeing to help alleviate any anxiety and fear they may have about COVID-19. Signpost to charities, support groups (including NHS Volunteer Responders), UK government guidance on supporting children and young people's mental health and wellbeing and Royal College of Paediatrics and Child Health resources for parents and carers. 1.2 Reassure
2020 National Institute for Health and Clinical Excellence - Clinical Guidelines
305. COVID-19 rapid guideline: community-based care of patients with chronic obstructive pulmonary disease (COPD)
guideline: community-based care of patients with chronic obstructive pulmonary disease (COPD) (NG168) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 4 of 131 1 Communicating with patients and minimising Communicating with patients and minimising risk risk 1.1 Communicate with patients, their families and carers, and support their mental health and wellbeing to help alleviate any anxiety and fear they may have about (...) is as stable as possible. This includes those with COVID-19, or who are suspected of having it. Keep their self-management plan up to date, and remind them that online video resources on correct inhaler technique are available. 2.2 At every interaction with a patient, be alert for new or increased issues with mental health and wellbeing, particularly anxiety and depression. 2.3 Find out if patients have advance care plans or advance decisions around ceilings of care, including 'do not attempt
2020 National Institute for Health and Clinical Excellence - Clinical Guidelines
306. COVID-19 rapid guideline: dermatological conditions treated with drugs affecting the immune response
) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 4 of 131 1 Communicating with patients and minimising Communicating with patients and minimising risk risk 1.1 Communicate with patients, their families and carers, and support their mental health and wellbeing to help alleviate any anxiety and fear they may have about COVID-19. Signpost to sources of online information (such as the British Association
2020 National Institute for Health and Clinical Excellence - Clinical Guidelines
307. COVID-19 rapid guideline: cystic fibrosis
the recommendations as the knowledge base and expert experience develops. COVID-19 rapid guideline: cystic fibrosis (NG170) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 4 of 111 1 Communicating with patients and minimising Communicating with patients and minimising risk risk 1.1 Communicate with patients, their families and carers, and support their mental health and wellbeing to help alleviate any anxiety and fear they may
2020 National Institute for Health and Clinical Excellence - Clinical Guidelines
308. COVID-19 rapid guideline: delivery of systemic anticancer treatments
and have been verified as far as possible. We will review and update the recommendations as the knowledge base and expert experience develops. © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 4 of 131 1 Communicating with patients Communicating with patients 1.1 Communicate with patients and support their mental wellbeing, signposting to charities and support groups where available, to help alleviate any anxiety
2020 National Institute for Health and Clinical Excellence - Clinical Guidelines
309. COVID-19 rapid guideline: dialysis service delivery
reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 4 of 171 1 Communicating with patients Communicating with patients 1.1 Communicate with patients and support their mental wellbeing to help alleviate any anxiety and fear they may have about COVID-19. Point them to resources such as Kidney Care UK. 1.2 T ell patients to alert their dialysis unit if they are unwell. Ask them and their carers to report COVID-19 relevant symptoms before leaving
2020 National Institute for Health and Clinical Excellence - Clinical Guidelines
310. COVID-19 rapid guideline: delivery of radiotherapy
, signposting to charities and support groups (including NHS volunteers) where available, to help alleviate any anxiety and fear they may have about COVID-19. 1.2 Minimise face-to-face contact by: • offering telephone or video consultations whenever possible • cutting non-essential face-to-face follow up, and minimising the number of on-treatment reviews • using alternative ways of delivering medicines, such as postal services, NHS volunteers, or drive-through pick-up points • using local services for blood
2020 National Institute for Health and Clinical Excellence - Clinical Guidelines
311. Colorectal cancer
treatments for colorectal cancer information about possible short-term, long-term, permanent and late side effects which can affect quality of life, including: pain altered bowel, urinary or sexual function nerve damage and neuropathy mental and emotional changes, including anxiety, depression, chemotherapy-related cognitive impairment, and changes to self-perception and social identity. Colorectal cancer (NG151) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms
2020 National Institute for Health and Clinical Excellence - Clinical Guidelines
312. COVID-19 rapid guideline: severe asthma
Foundation) to help alleviate any anxiety and fear they may have about COVID-19. 1.2 Be aware that severe asthma is defined by the European Respiratory Society and American Thoracic Society as asthma that requires treatment with high- dose inhaled corticosteroids (see inhaled corticosteroid doses for NICE's asthma guideline) plus a second controller (and/or systemic corticosteroids) to prevent it from becoming 'uncontrolled' , or which remains 'uncontrolled' despite this therapy. 1.3 Some patients
2020 National Institute for Health and Clinical Excellence - Clinical Guidelines
313. COVID-19 rapid guideline: rheumatological autoimmune, inflammatory and metabolic bone disorders
and support groups (such as ARMA, which has a list of relevant organisations, and NHS Volunteer Responders) where available, to help alleviate any anxiety and fear they may have about COVID-19. 1.2 Minimise face-to-face contact by: • cutting non-essential face-to-face consultations • offering telephone or video consultations • contacting patients via text message or email • making use of departmental pages on local NHS trust websites • using rheumatology department advice services, including out-of-hours
2020 National Institute for Health and Clinical Excellence - Clinical Guidelines
314. COVID-19 rapid guideline: managing suspected or confirmed pneumonia in adults in the community
to contact. 1.2 Support patients' mental wellbeing, signposting to charities and support groups (including NHS volunteers) where available, to help alleviate any anxiety and fear they may have about COVID-19. 1.3 Minimise face-to-face contact by: • offering telephone or video consultations (see the BMJ guidance on COVID-19: a remote assessment in primary care for a useful guide, including a visual summary for remote consultations) • cutting non-essential face-to-face follow-up • using electronic rather (...) of hospital admission include improved diagnostic tests (chest X-ray, microbiological tests and blood tests) and respiratory support • the risks and disadvantages of hospital admission include spreading or catching COVID-19 and loss of contact with families. Managing breathlessness Managing breathlessness 4.4 Be aware that severe breathlessness often causes anxiety, which can then increase breathlessness further. See the NICE COVID-19 rapid guideline on managing symptoms (including at the end of life
2020 National Institute for Health and Clinical Excellence - Clinical Guidelines
315. COVID-19 rapid guideline: managing symptoms (including at the end of life) in the community
-and- conditions#notice-of-rights). Page 2 of 19Contents Contents Overview 4 1 Communicating with patients and minimising risk 5 2 Treatment and care planning 6 3 General advice for managing COVID-19 symptoms 7 4 Managing cough 8 5 Managing fever 10 6 Managing breathlessness 11 7 Managing anxiety, delirium and agitation 15 8 Managing medicines for patients with COVID-19 17 9 Prescribing anticipatory medicines for patients with COVID-19 18 10 Healthcare workers 19 COVID-19 rapid guideline: managing symptoms (...) ) in the community (NG163) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 4 of 191 1 Communicating with patients and minimising Communicating with patients and minimising risk risk 1.1 For patients with COVID-19 symptoms explain: • that the key symptoms are cough, fever, breathlessness, anxiety, delirium and agitation but they may also have fatigue, muscle aches and headache • that they and people caring for them should follow
2020 National Institute for Health and Clinical Excellence - Clinical Guidelines
316. COVID-19 rapid guideline: haematopoietic stem cell transplantation
(NG164) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 5 of 181 1 Communicating with patients and minimising Communicating with patients and minimising risk risk 1.1 Communicate with patients, their families and carers and support their mental wellbeing, signposting to charities and support groups (including NHS volunteers) where available, to help alleviate any anxiety and fear they may have about COVID-19. 1.2
2020 National Institute for Health and Clinical Excellence - Clinical Guidelines
317. Tinnitus: assessment and management
alongside the Tinnitus Functional Index in adults with tinnitus if further assessment of the psychological effects of tinnitus is needed. 1.3.8 If there are concerns about depression or anxiety in adults, a healthcare professional competent in mental health assessment should: • carry out an assessment using a questionnaire (for example, those in the recommendations on assessment in the NICE guideline on common mental health problems), or an ability-appropriate measure • consider assessment using (...) acknowledged that the Insomnia Severity Index is not commonly used in current practice but it is an appropriate measure and is freely available and easy to use. The questionnaire can also be used as a screening tool which can lead to a referral. No evidence was identified that evaluated the clinical or cost effectiveness of questionnaires to assess the psychological impact of tinnitus. Tinnitus can cause depression or anxiety and can be exacerbated by depression or anxiety, leading to distress
2020 National Institute for Health and Clinical Excellence - Clinical Guidelines
318. Space from Depression for treating adults with depression
, to measure severity of anxiety symptoms. T o compare, the national average starting and finishing PHQ-9 values are shown for people having guided self-help (using books) in IAPT services, and for people having any treatment in IAPT services. Across the 3 services, the change in PHQ-9 values was -3.7 for people who had Space for Depression, compared with -6.6 for people who had standard care. For comparison, the national change in PHQ-9 values for people having guided self-help (using books) was -5.0
2020 National Institute for Health and Clinical Excellence - Advice
319. EarlyCDT-Lung for cancer risk classification of indeterminate pulmonary nodules
such as pneumothorax and bleeding. Two specialists felt that patient exposure to CT scans would be reduced, as well as lessening anxieties over false positive results. Another noted that the early detection of malignant tumour is a potential benefit to the patient. One specialist noted that people with IPN who have comorbidities will benefit from EarlyCDT-Lung. Another felt people in socioeconomically deprived areas will benefit. One specialist noted that it would be interesting to know what effect early detection
2020 National Institute for Health and Clinical Excellence - Advice
320. Auricular acupuncture in prescription drug dependence detoxification
doses, aid in treatment retention and completing, and be a useful adjunct to address psychosocial aspects of recovery.” References Baker TE, Chang G. The use of auricular acupuncture in opioid use disorder: A systematic literature review. American Journal on Addictions 2016;25:592-602. Bergdahl L, Broman JE, Berman AH, Haglund K, von Knorring L, Markström A. Auricular acupuncture versus cognitive behavioural therapy in the discontinuation of hypnotic drug usage, and treatment effects on anxiety (...) , depression and insomnia symptoms − a randomised controlled study. European Journal of Integrative Medicine 2017;16:15-21. Black S, Carey E, Webber A, Neish N, Gilbert R, Black S, et al. Determining the efficacy of auricular acupuncture for reducing anxiety in patients withdrawing from psychoactive drugs. Journal of Substance Abuse Treatment 2011;41:279-287. SBU Enquiry Service Consists of structured literature searches to highlight studies that can address questions received by the SBU Enquiry Service